OKAMOTO, K., WANG, W., JACOBS, D.O. and TERAI, C. Activation of Multiple Signaling Pathways by Terminal Complement Complexes Involved in Myocellular
Sodium Homeostasis. Tohoku J. Exp. Med., 2004, 202 (2) , 113-122 Soluble C5b-9 complexes (SC5b-9), hemolytically inactive end-products of complement activation have long been considered to be irrelevant. Recent investigations, however, have demonstrated that SC5b-9 induces numerous biological effects via a series of intracellular signal transduction events. We have previously demonstrated that SC5b-9 enriched sera increased intracellular Na + in rat skeletal muscles. This study was purposed to determine if the protein kinase C (PKC) or mitogen-activated protein kinase (MAPK) signaling pathway mediates the effects of SC5b-9. Fast-twitch extensor digitorum longus (EDL) muscles isolated from infant rats were incubated at 30°C for 60 minutes with 10% zymosan-activated rat sera (ZARS) as a source of complement. Heat-inactivated rat sera (HIRS) were used as a control. The muscles were also incubated with ZARS or HIRS in the presence of specific inhibitors against PKC (GF109203X) or MAPK (PD98059 and SB202190). Intracellular Na + and K + contents were then measured. ZARS significantly increased intracellular Na + and the Na + /K + ratio in EDL muscles as compared to HIRS. GF109203X, PD98059 and SB202190 markedly attenuated increase in myocellular Na + induced by ZARS, respectively. We concluded that SC5b-9 enriched sera alter myocellular Na + homeostasis, at least in part, via the mechanisms linked to PKC and MAPK signal transduction pathways.
C5b-9 complexes; sodium and potassium transport; protein kinase C; mitogen-activated protein kinase; skeletal muscle © 2004 Tohoku University Medical Press Sepsis is characterized by excessive complement activation, the degree of which correlates with the severity of septic shock and mortality (Heideman et al. 1988) . During severe systemic infection, an increase in myocellular Na + is commonly observed (Sayseed 1987) . Although the mechanisms responsible for the ionic changes are not fully understood, alterations in the Na + -K + -ATPase pump (NKA) activity on the cellular membrane play a central role (Sayseed 1987) .
We have previously demonstrated that sublytic activation of the terminal complement pathway directly increases intracellular Na + in isolated skeletal muscles (Okamoto et al. 2000; Wang et al. 2001 ). One of the major end-products of the terminal complement activation is the membranebound C5b-9 complex, also known as the membrane attack complex (MAC). The MAC forms pores in cellular membranes, thereby altering ion gradients and causing lysis of some target cells (Shin and Carney 1988) , whereas another product of the terminal complement activation, soluble C5b-9 complexes (SC5b-9) have long been considered to be irrelevant and inactive. Recent investigations, however, have clearly demonstrated that SC5b-9 and SC5b67 induce numerous biological effects via a series of intracellular signal transduction events (Ishikawa et al. 1993; Wang et al. 1996; Tedesco et al. 1997) . We have also demonstrated that SC5b-9-enriched complement sera may alter NKA activity in resting skeletal muscles, at least in part, through pertussis toxinsensitive G proteins (Wang et al. 2001) .
It has been reported that terminal complement complexes stimulate multiple signal transduction pathways involving protein kinase C (PKC) and/or mitogen-activated protein kinase (MAPK) in various cells (Carney 1990; Niculescu et al. 1997) . Elevation of cytosolic Ca 2+ via Ca 2+ influx through membrane channels by MAC is believed to be a major signal to these pathways.
Recent studies, however, shows that hemolytically inactive terminal complexes can also induce a dose-dependent increase in intracellular Ca 2+ (Wang et al. 1996) and directly stimulate several cellular processes such as phosphorylation of MAPK (Bhattacharya et al. 2001) . Interestingly, both PKC and MAPK pathways appear to be directly or indirectly associated with factors that regulate NKA pump activity (Therien and Blostein 2000) . The purpose of this study was, therefore, to determine if PKC and/or MAPK signal transduction pathways help mediate alterations in myocellular Na + induced by SC5b-9-enriched complement sera in incubated skeletal muscle preparations.
MATERIALS AND METHODS Chemicals
GF109203X, PD98059 and SB202190 were purchased from Calbiochem-Novabiochem Company (La Jolla, CA, USA). All other chemicals were from Sigma Chemical Company (St. Louis, MO, USA).
Animals
Male, Sprague-Dawley rats (Harlan SpragueDawley, Incorporation, Indianapolis, IN, USA), weighing 40-50 g, were acclimatized to a 12-hour light/dark cycle for 3 days, and housed at a constant temperature of 22°C with 50-70% humidity before any experiments were initiated. During this time, all animals were allowed standard rodent chow and water ad libitum.
Muscle preparation and incubation
The experimental conditions employed were those previously described by Everts and Clausen (1992) and modified by James et al. (1996) . After acclimatization, the rats were weighed (approximately 50-70 g) and anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg body weight). The hindlimb extensor digitorum longus (EDL) muscles were carefully dissected with the tendons intact. Immediately after dissection, each EDL muscle was mounted on a solid support at resting length, transferred to a 25-ml flask (1 muscle/flask) and preincubated for 30 minutes in normal Krebs-Henseleit buffer (KHB: 118 mM NaCl, 25.3 mM NaHCO 3 , 6 mM KCl 4, 1.16 mM KH 2 PO 4 , 1.16 mM MgSO 4 , 2.5 mM CaCl 2 , 10 mM D-glucose, pH 7.4) in a shaking water bath in order to remove blood contamination and to equilibrate extracellular fluid with media. After preincubation, the media were discarded and each muscle was blotted, weighed, transferred to a 25-ml flask and incubated for 60 minutes in normal KHB containing 10% diluted zymosan-activated or 10% diluted heat-inactivated rat sera as described below. To evaluate PKC involvement, a highly selective inhibitor of PKC, GF109203X (Chibalin et al. 2001 ) (4 or 10 μ M) was added to the preincubation and incubation media. To selectively inhibit the p42/44 MAPK and p38 MAPK cascades, a specific inhibitor of mitogenactivated protein-extracellular signal-regulated kinase kinase-1/2 (MEK-1/2), PD98059 (25 μ M) (Hayashi et al. 1999) , or a specific p38
MAPK inhibitor, SB202190 (12.5 μ M) (Singh et al. 1999 ) was also added to the preincubation and incubation media. Preincubation and incubation of the EDL muscles were performed at 30°C. The bulk media were oxygenated via continuous bubbling of 95% O 2 -5% CO 2 for 20 minutes, then 3 ml of media were pipetted into the tightly stoppered 25-ml flask, so that sufficient oxygen was supplied to the muscle in the media during in vitro incubation (James et al. 1996) . GF109203X, PD98059 and SB202190 were dissolved in DMSO and added to the media immediately before each experiment. The maximal concentration of DMSO used was 0.1%, which did not affect any assay.
Zymosan-activated rat sera
Homologous normal rat sera (Sigma Chemical Company, St. Louis, MO, USA) were used as a complement source in this study. To activate the complement system, normal rat sera were treated with zymosan in vitro as described previously (Ishikawa et al. 1993) . Briefly, zymosan was boiled in normal saline for 10 minutes, cooled to room temperature, washed twice, suspended in 1-ml aliquots containing 4 or 10 mg zymosan in normal saline, and kept frozen at -20°C until used. Before the experiment, one aliquot of zymosan was thawed, centrifuged, and resuspended in 1 ml of normal rat serum. The mixtures were incubated at 37°C for 60 minutes with shaking. Zymosan particles were removed from the sera by centrifugation at 14 000×g for 5 minutes to exclude any non-complement effects (Tedesco et al. 1997) . Because no target cell membranes were available for the MAC assembly in cell-free rat sera during zymosan activation, SC5b-9 complexes are predominantly formed in zymosan-activated rat sera (ZARS) (Morgan 1999) . A 10% dilution of ZARS was chosen for all subsequent experiments, because this amount of ZARS causes sublytic complement activation (Lang et al. 1997; Okamoto et al. 2000) . Heatinactivated rat sera (HIRS) were used as a control and were prepared by incubating normal rat sera at 56°C for 30 minutes with shaking. This procedure selectively inactivates all complement activity. The ZARS or HIRS were used within 10-15 minutes after their activation or inactivation, respectively.
Intracellular Na + and K + Contents in EDL Muscles
Immediately after incubation, each EDL muscle was blotted, weighed and washed four times for 15 minutes each in a 25-ml flask containing 3 ml ice-cold Na + -and K + -free Trissucrose buffer (10 mM Tris-HCl, 263 mM sucrose, pH 7.4) in a shaking water bath to remove extracellular Na + (Everts and Clausen 1992) . The bulk Tris-sucrose buffer was oxygenated by continuous bubbling of 95% O 2 -5% CO 2 at 0°C for 30 minutes before the solution was pipetted into tightly stoppered 25 ml-flasks. Each flask was then individually gassed with the same mixture and tightly stoppered. After a 4×15 minutes washout treatment, each EDL muscle was blotted, weighed, and, then, soaked overnight in 2 ml of 0.38 M trichloroacetic acid. The muscle was homogenized using a sonicator (Model XL-2015 
Lactate dehydrogenase (LDH) assay
To assess the degree of muscle injury that might occur during incubation, the LDH activity in the incubation media was determined using a quantitative lactate dehydrogenase assay kit (Sigma Chemical Compamy, St. Louis, MO, USA). In a separate experiment (Okamoto et al. 2000) , total LDH activity was measured by homogenizing the EDL muscles isolated from normal rats. The supernatant was collected by centrifugation and LDH activity was measured. The average value obtained was considered to represent total LDH activity and was used to calculate the percentage of LDH released (% LDH) into the media.
Statistical analysis
All the results are expressed as the mean± S.E. Statistical analysis was performed by analysis of variance (ANOVA) using STATISTICA for windows Release 4.3 software (StatSoft Incorporation, Tulsa, OK, USA). Post-hoc pairwise comparisons were made by Fisher's Least Significant Difference test when appropriate. Probability values less than 0.05 were considered significant.
RESULTS
The average wet weight of the EDL muscles before or after 1-h incubation was 23.1-30.5 mg or 23.3-31.1 mg, respectively. The average % LDH release was 3.9-6.8%. There were no significant differences in wet weight gain or LDH release during incubation between any corresponding ZARS and HIRS groups.
[ ] i ratios were significantly increased when EDL muscles were exposed to ZARS as compared to exposure to KHB or HIRS (Fig. 1) (Fig. 2) . The ionic alterations appeared to be equivalent between the two concentrations of GF109203X. These data suggest that conventional or novel PKC isoforms may be involved in the action of ZARS.
To determine if MAPK signal transduction 
DISCUSSION
SC5b-9 has long been considered to be an irrelevant end-product of complement activation. However, recent studies have shown that SC5b-9 can induce more biological changes than previously assumed. Ishikawa et al. (1993) showed that SC5b-9-enriched sera attenuate the lung endothelial barrier in vitro. SC5b-9 derived from purified components binds cultured vascular endothelial cells and upregulates the expression of multiple adhesion molecules (Tedesco et al. 1997) . Furthermore, Wang et al. (1996) found that soluble C5b67 complexes stimulate chemotaxis responses and inhibit superoxide production in polymorphonuclear leukocytes. The mechanisms responsible for the action of these hemolytically inactive end-products are, however, not completely understood.
Skeletal muscle cells are normally shielded from complement by the vascular endothelial barrier, but sepsis attenuates such passive barriers resulting in increased capillary permeability and complement protein-rich fluid leakage (Hazelzet et al. 1998) . Thus, it is quite likely that the complement activation, which occurs during sepsis, produces a large amount of SC5b-9 not only in plasma but also around the target cells by leakage or by local assembly. We have previously demonstrated that changes in myocellular Na + induced by SC5b-9-enriched zymosan-activated rat sera (ZARS) are inhibited by treatment of muscles with a specific inhibitor of G i /G o proteins, pertussis toxin, and that ZARS's effects appear to be Ca 2+ -dependent (Wang et al. 2001) . The data are consistent with recent studies showing that signal activation by soluble C5b67 complexes involves pertussis toxin-sensitive G-proteins in leukocytes (Wang et al. 1996) . Thus, G-protein signal transduction is likely linked to the SC5b-9-mediated actions. Of interest in this regard are observations that SC5b-9 is able to adhere to cultured skeletal muscle myoblasts or perfused single pulmonary microvessels through the interaction of its vitronectin components with an integrin α v β 3 vitronectin receptor by means of its RGD (Arg-Gly-Asp) tripeptide sequence (Biesecker 1990; Ishikawa et al. 1993) . A recent study has demonstrated that SC5b-9, which ligates the α v β 3 -integrin via its vitronectin molecules, activates MAPK and phospholipase C (PLC) through enhanced tyrosine phosphorylation in bovine pulmonary artery endothelial cells (Bhattacharya et al. 2001) . Furthermore, tyrosine phosphorylation of PLC activates PKC via its effect on diacylglycerols (DAG) (Nishizuka 1984) . Because both PKC and MAPK appear to be directly or indirectly associated with the regulation of NKA activity (Kometiani et al. 1998; Therien and Blostein 2000) , the role of PKC and/or MAPK in SC5b-9 induced myocellular Na + alterations is worthy of investigation.
PKC is a phospholipid-dependent serine/ threonine kinase that plays a major role in transducing signals generated by growth factors, hormones and neurotransmitters (Nishizuka 1984) . PKC is activated by DAG and serves as the receptor for exogenous tumor-promoting agents such as phorbol ester. In the present study, the increases in myocellular [Na + ] i and [Na + ] i /[K + ] i induced by ZARS were significantly attenuated in the presence of the PKC inhibitor, GF109203X, at both 4 μ M and 10 μ M. GF109203X inhibits conventional and novel PKC isoforms at 1 μ M but all the PKCs, including atypical PKC isoform, at higher concentrations (>5 μ M) (Li et al. 1999; Chibalin et al. 2001 ). GF109203X does not directly affect phosphorylation status of the NKA in rat skeletal muscle (Chibalin et al. 2001) . Thus, our data strongly suggest that conventional or novel PKC isoforms may be involved in the signal transduction of the action of ZARS.
MAPKs are proline-directed serine/threonine protein kinases that respond to a variety of extracellular stimuli including hormones, growth factors and cytokines (Marshall 1995) . Three subgroups of the MAPK superfamily have been identified: the extracellular signal regulated kinase (ERK-1/2 or p42/44 MAPK ); the c-Jun NH 2 -terminal kinases (JNK or p46/54 JNK ) and the p38 MAPK . Although MAPK families are structurally related, they are generally activated by distinct extracellular stimuli through distinct upstream dual specificity kinases, thus comprising a series of separate MAPK cascades. PD98059 is a specific inhibitor of the mammalian MAP kinase kinase (MEK), an upstream kinase of ERK, and has been used widely to examine the physiological function of p42/44 MAPK pathway (Hayashi et al. 1999 ). PD98059 at 25 μ M completely blocks the contraction or insulin-induced phosphorylation of p42 MAPK and p44 MAPK isoforms in rat skeletal muscles. SB202190 is a highly selective inhibitor of p38 MAPK and does not affect the other relevant kinases even at high concentrations (Singh et al. 1999 ). In the current study, we have shown that SB202190 completely abrogated ZARS-induced increases in myocellular [Na + MAPK also contributes to ZARS's effects. Ryder et al. (2000) have demonstrated that both PD98059 and SB203580 (an inhibitor of p38 MAPK ) inhibit contraction-stimulated ERK-1/2 phosphorylation in rat skeletal muscle. It remains unclear, however, whether a cross-talk between the p42/44 MAPK and p38 MAPK pathway exist. Nevertheless, our results imply that multiple intracellular signaling might be involved in ZARS's effects on myocellular Na + homeostasis. NKA is a membrane-bound enzyme that actively maintains the transmembrane Na + gradient by hydrolyzing ATP as its energy source. Because of its importance in the maintenance of intracellular Na + homeostasis, it is crucial for NKA activity to be functionally modulated in response to cellular homeostasis and physiological stimuli. For example, it has been well documented that multiple hormones can regulate the NKA activity via intracellular signaling events that involve protein kinases and phosphatases (Therien and Blostein 2000) . In our previous study (Wang et al. 2001 ), presence of a specific inhibitor of NKA, ouabain, myocellular [Na + ] i and [K + ] i were equivalent in the HIRS and ZARS groups. This finding suggests that impairment of ouabainsensitive NKA activity may be involved in the alterations of myocellular Na + homeostasis induced by ZARS. Regulation of the NKA occurs through diverse and tissue-specific mechanisms (Therien and Blostein 2000) . Although we did not directly examine whether the effects of ZARS on myocellular Na + homeostasis are due to the inhibition of the NKA activity by PKC and/or MAPK activation, numerous studies have demonstrated that activation of PKC or MAPK can, indeed, inhibit the NKA activity. To our knowledge, two mechanisms by which PKC could inhibit the NKA activity have been proposed: by direct phosphorylation of the Na + pump at serine sites within the α -subunit (Chibalin et al. 1999) or by activation of the PLA 2 -eicosanoid pathway (Ominato et al. 1996) . Most recently, it has been reported that exposing myocytes to phorbol 12-myristate 13-acetate (PMA) reduces the apparent affinity of Na + pump for Na + relative to K + at intracellular binding sites (Buhagiar et al. 1999) . Similarly, activation of p42/44 MAPK and p38 MAPK pathways has also been shown to inhibit the NKA activity via the cPLA 2 -eicosanoid pathway (Ominato et al. 1996; Therien and Blostein 2000) . Interestingly, the PKC and MAPK pathways are closely linked. PKC has been recognized as an upstream activator of Raf-1 that activates MEK (Kolch et al. 1993) . PKC is also implicated in p38 MAPK activation in rat ventricular myocytes (Clerk et al. 1998) . Therefore, it is reasonable to hypothesize that ZARS-induced alterations in myocellular [Na + One may argue that the effects of MAC and other intermediate complement products including C3a and C5a may contribute to myocellular Na + alterations induced by ZARS. Because all sera employed were cell-free and because components of complement in sera were completely consumed during zymosan activation (Ishikawa et al. 1993; Morgan et al. 1999) , no membranes or minimal amount of precursors for MAC formation were available. Our previous study (Okamoto et al. 2000) showed that incubation of skeletal muscles with C7 or C9 deficient heterologous human sera (in both cases, complement activation does not proceed beyond the formation of C5b-6 or C5b-8, respectively) did not alter myocellular [Na + ] i , but reconstruction with C7 or C9 significantly increased myocellular [Na + ] i . These results suggest that the intermediate products of complement activation are not likely involved in the effects induced by ZARS. Thus, we believe that SC5b-9 is likely the primary components in ZARS that alter myocellular Na + homeostasis.
CONCLUSION
We have demonstrated that SC5b-9-enriched ZARS alters Na + homeostasis in isolated fasttwitch skeletal muscle. The mechanisms responsible for the action of ZARS is, at least in part, linked to the PKC and/or MAPK signaling transduction pathways. Although the in vitro data do not precisely reflect what occurs in vivo during sepsis, our study provides direct evidence that selective inhibition of complement activation and its intracellular signaling transduction by pharmacological means could suppress complementmediated disease processes.
